RIZZI LAURA

Meanti, R., Bresciani, E., Rizzi, L., Molteni, L., Coco, S., Omeljaniuk, R., et al. (2025). Cannabinoid Receptor 2 (CB2R) as potential target for the pharmacological treatment of neurodegenerative diseases. BIOMÉDECINE & PHARMACOTHÉRAPIE, 186(May 2025) [10.1016/j.biopha.2025.118044]. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Potential application of Growth Hormone Secretagogues (GHS) for Amyotrophic Lateral Sclerosis (ALS) treatment: mechanisms of action and neuroprotective effects characterization in human SH-SY5Y SOD1G93A cells. Intervento presentato a: Innovazione e malattie rare: dalla ricerca preclinica al paziente, Bari, Italia. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Molteni, L., Omeljaniuk, R., et al. (2024). Selected Growth Hormone Secretagogues (GHS) as disease modifiers in an in vitro model of Amyotrophic Lateral Sclerosis: a proof-of-concept study. Intervento presentato a: 9th European Congress of Pharmacology (EPHAR 2024), Atene, Grecia. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Licata, M., Sartori, E., Omeljaniuk, R., et al. (2024). Selected Growth Hormone Secretagogues (GHS) as promising therapeutical approach for Amyotrophic Lateral Sclerosis: a proof-of-concept study. Intervento presentato a: 42° Congresso Nazionale SIF. Science today for a better medicine tomorrow, Sorrento, Italia. Dettaglio

Meanti, R., Rizzi, L., Bresciani, E., Molteni, L., Locatelli, V., Torsello, A. (2023). Development of Growth Hormone Secretagogues as new therapeutical tools for Amyotrophic Lateral Sclerosis. Intervento presentato a: Twentieth National Congress of the Italian Society for Neuroscience (SINS2023), Torino, Italia. Dettaglio